Recruitment status changed
Before: Not yet recruiting. After: Recruiting.
Study sponsor: Inhibikase Therapeutics
Primary completion is the date data collection ends for the main study measures, not when results are published.
Before: Not yet recruiting. After: Recruiting.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: [Part A] To evaluate the effect on PVR in participants with WHO Group 1 PAH treated with IKT-001 compared to placebo Measure: [Part B] To characterize the effects of IKT-001 on symptoms and characteristics of Pulmonary Arterial Hypertension compared to placebo. After: Measure: [Part A] To evaluate the effect on Pulmonary Vascular Resistance (PVR) in participants with WHO Group 1 PAH treated with IKT-001 compared to placebo Measure: [Part B] To characterize the effects of IKT-001 on symptoms and characteristics of Pulmonary Arterial Hypertension compared to placebo.